SLS icon

SELLAS Life Sciences

1.91 USD
+0.00
0.00%
At close Aug 25, 4:00 PM EDT
Pre-market
1.88
-0.03
1.57%
1 day
0.00%
5 days
9.77%
1 month
6.11%
3 months
-1.04%
6 months
69.03%
Year to date
78.50%
1 year
44.70%
5 years
-18.03%
10 years
-100.00%
 

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 15

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

8,320% more call options, than puts

Call options by funds: $18M | Put options by funds: $214K

567% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 6

259% more capital invested

Capital invested by funds: $15.4M [Q1] → $55.4M (+$39.9M) [Q2]

150% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 8

75% more funds holding

Funds holding: 44 [Q1] → 77 (+33) [Q2]

9.6% more ownership

Funds ownership: 15.73% [Q1] → 25.33% (+9.6%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$7
266%
upside
Avg. target
$7
266%
upside
High target
$7
266%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Maxim Group
Jason McCarthy
266%upside
$7
Buy
Maintained
16 Jul 2025

Financial journalist opinion

Based on 3 articles about SLS published over the past 30 days

Positive
Seeking Alpha
6 days ago
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicability. GPS's REGAL final analysis at 80 events expected should come by year-end 2025. Its prior data suggest survival advantages versus historical controls.
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
Neutral
GlobeNewsWire
2 weeks ago
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
-        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events        - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), and has issued a positive recommendation to continue the trial without modification. The IDMC concluded that the risk-benefit profile of GPS supports continued evaluation under the current study protocol.
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
Positive
Zacks Investment Research
3 weeks ago
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
Neutral
GlobeNewsWire
1 month ago
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD.
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
Positive
Zacks Investment Research
2 months ago
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
GlobeNewsWire
2 months ago
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key Inflection Points This Year
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
Neutral
GlobeNewsWire
2 months ago
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical efficacy of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer lines. The data are featured in a presentation, entitled “In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines” at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30- June 3, 2025, in Chicago, Illinois.
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
Neutral
GlobeNewsWire
3 months ago
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on Wednesday, May 21, 2025 at 8:20 am ET.
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
Neutral
GlobeNewsWire
3 months ago
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) - First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD)
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
Neutral
GlobeNewsWire
3 months ago
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients –
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Charts implemented using Lightweight Charts™